Objective:We determined whether the prostaglandin inhibitor sulindac crosses the human placenta.
Methods:The recirculating single-cotyledon placenta model was used to characterize the matenal-to-fetal and fetal-to-maternal transport of 14C-labeled sulindac in normal term placentas perfused immediately after delivery. Antipyrine was added as a standard for simple diffusion. Serial samples were taken from bth reservoirs during each 3-hour perfusion. Transport was calculated using liquid scitntillation spectrometry for 14C-labeled sulindac and high-performance liquid chromatography for antipyrine.
Results:There was significant maternal-to-fetal transfer of sulindac. The mean (±SD) transfer at 2 hours was 7.22 ± 2.57%. The fetal-to-maternal transfer was similar at 10.75 ± 3.80%. The mean maternal/fetal concentration ratio of sulindac was 0.42 at 3 hours. Placental uptake ranged from 24-45 ng/g of placenta.
Conclusions:Sulindac crosses the human placenta in small but significant amounts. The transport is similar in both directions, implying simple diffusion.
1. Zuckerman H, Shaler E, Gilad G, Katzunl E. Further study of the inhibition of premature labor by indomethacin: Part II. Double-blind study. J Perinat Med1984;12:25-29.
2.
2. Niebyl JR, Blake DA, White RD, et al. The inhibition of premature labor with indomethacin. Am J Obstet Gynecol1980;136:1014-1019.
3.
3. Moise KJ, Huhta JC, Sharif DS, et al. Indomethacin in the treatment of premature labor: Effects on the fetal ductus arteriosus. N Engl J Med1988;319:327-331.
4.
4. Besinger RE, Niebyl JR, Keyes WG, Johnson TRB. Randomized comparative trial of indomethacin and ritodrine for the long-term treatment of preterm labor. Am J Obstet Gynecol1991;164:981-988.
5.
5. Kirshon B, Moise KJ, Mari G, Willis R. Long-term indomethacin therapy decreases fetal urine output and results in oligohydramnios. Am J Perinatol1991;8:86-88.
6.
6. Ciabattoni G, Bass AH, Patrignane P, et al. Effects of sulindac on renal and extrarenal eicosanoid synthesis. Clin Pharmacol Ther1987;41:380-383.
7.
7. Brogden RN, Heel RC, Speight TM, Avery GS. Sulindac: A review of its pharmacological properties and therapeutic efficacy in rheumatic diseases. Drugs1978;16:97-114.
8.
8. Duggan DE, Hare LE, Ditzler BA, Lei BW, Kwan KC. The disposition of sulindac. Clin Pharmacol Ther1976;21:326-335.
9.
9. Carlan SJ, O'Brien WF, O'Leary TD, Mastrogiannis D. Randomized comparative trial of indomethacin and sulindac for the treatment of refractory preterm labor. Obstet Gynecol1992;70:223-227.
10.
10. Hucker HB, Stauffer SC, White SD, et al. Physiologic disposition and metabolic fate of a new anti-inflammatory agent, Cis-5-Fluoro-2-Methyl-1-[p-(methylsulfinyl)-Benzlidenyl]-indene-3-acetic acid in the rat, dog, rhesus monkey, and man. Drug Metab Dispos1973;1:721-736.
11.
11. Brandes JM, Tavoline N, Potter BJ, et al. A new recycling technique for human placental cotyledon perfusion: Application to studies of the fetomaternal transfer of glucose, insulin, and antipyrine. Am J Obstet Gynecol1983;146:800-806.
12.
12. Riley CA, Evans WE. Simultaneous analysis of antipyrine and lorazepam by high-performance liquid chromatography. J Chromatogr1986;382:199-205.
13.
13. Dusci LJ, Hackett LP. Determination of sulindac and its metabolites in serum by high-performance liquid chromatography. J Chromatogr1979;171:390-393.
14.
14. Elliott BD, Langer O, Schenker S, Johnson RF. Insignificant transfer of glyburide occurs across the human placenta. Am J Obstet Gynecol1991;165:807-812.
15.
15. Leveno KJ, Little BB, Cunningham FG. The national impact of ritodrine hydrochloride for inhibition of preterm labor. Obstet Gynecol1990;76:12-15.
16.
16. Kubli F. Discussion. In: Anderson A, Beard R, Brudenell JM, Dunn PM, eds. Proceedings of the Fifth Study Group of the Royal College of Obstetricians and Gynaecologists. London: Royal College of Obstetricians and Gynaecologists, 1977:218-220.
17.
17. Higby K, Xenakis EMJ, Pauerstein CJ. Do tocolytic agents stop preterm labor? A critical and comprehensive review of efficacy and safety. Am J Obstet Gynecol1992;168:1247-1259.
18.
18. Groome LJ, Goldenberg RL, Cliver SP, et al. Neonatal periventricular-intraventricular hemorrhage after maternal β-sympathomimetic tocolysis. Am J Obstet Gynecol1992;167:873-879.
19.
19. Schenker S, Johnson R, Hays S, Ganeshappa R, Henderson G. Effects of nicotine and nicotine ethanol on human placental amino acid transfer. Alcohol1989;6:289-296.
20.
20. Schenker S, Dicke J, Johnson R, Mor L, Henderson G. Human placental transport of cimetidine. J Clin Invest1987;80:1428-1434.
21.
21. Fortunato SJ, Bawdon RE, Swan KF, et al. Transfer of timentin (ticarcillin and clavulanic acid) across the in vitro perfused human placenta: Comparison with other agents. Am J Obstet Gynecol1992;167:1595-1599.
22.
22. Moise KJ, Ou CN, Kirshon B, et al. Placental transfer of indomethacin in human pregnancy. Am J Obstet Gynecol1990;162:549-554.
